You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Widely Tunable High Power Quantum Cascade Laser Arrays for Standoff Detection

    SBC: EOS Photonics            Topic: A14AT015

    To achieve the goals of this program improving spectral coverage and output power of monolithic QCL sources as well as the development of a production and manufacturing plan - we propose to develop in collaboration with MIT Lincoln Laboratory a broadly tunable high power source that is based on Eos"proprietary QCL array technology. The current generation of Eos"commercially available fully packag ...

    STTR Phase I 2014 Department of DefenseArmy
  2. Parallel Two-Electron Reduced Density Matrix Based Electronic Structure Software for Highly Correlated Molecules and Materials

    SBC: RDMChem LLC            Topic: A14AT013

    Two-electron reduced-density-matrix (2-RDM) methods represent all of the electrons in any molecule or material with only two electrons by replacing the wave function by the 2-RDM as the basic variable for quantum many-electron theory. The 2-RDM methods, developed by David Mazziotti at The University of Chicago with support from the Army Research Office, have polynomial scaling with system size, al ...

    STTR Phase I 2014 Department of DefenseArmy
  3. Silica Colloidal Crystals for High Resolution MALDI-MS of Glycoproteins

    SBC: LI-COR, Inc.            Topic: 100

    DESCRIPTION provided by applicant The product is a slide coated with silica colloidal crystals to combine protein electrophoresis with matrix assisted laser desorption ionization mass spectrometry MALDI MS detection giving superior performance in both The Phase II proposal will be to develop an instrument for facile application of the slide in proteomics of intat glycoproteins This propos ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Pathogen Specific Antimicrobial Coatings for Fabrics

    SBC: GINER INC            Topic: A14AT012

    Antimicrobial treatment of military textile systems is intended to provide enhanced protection to the Warfighter in the field by preventing colonization of harmful bacteria that cause problems such as odor, dermatitis, and skin irritation. Current treatments can impart antimicrobial functionality to textiles; however, they all possess broad-spectrum antimicrobial activity, affecting all skin bacte ...

    STTR Phase I 2014 Department of DefenseArmy
  5. Few-optical-cycle LWIR laser system

    SBC: Q-PEAK INCORPORATED            Topic: A14AT006

    Q-Peak, Inc. in collaboration with CREOL proposes to develop a novel concept of long-wave IR (LWIR) femtosecond laser system. Current laser systems suffer from complexity due to the use of multiple nonlinear stages to achieve the desired wavelength and have issues with power scaling. The proposed system will consist of 2.5 um femtosecond regenerative amplifier system pumping a single OPA stage bas ...

    STTR Phase I 2014 Department of DefenseArmy
  6. Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government